Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Amgen Inc

AMGN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mega Cap Analyst: HOLD

Last Close

$415.21

▼ -0.63%

Market Cap $224.48B · Vol 876.48K

Key Metrics

P/E Ratio

25.79

FWD: 17.38

Market Cap

$224.48B

Mega Cap

Div Yield

2.41%

Quarterly dividend

EPS Growth

+5.41%

YoY

RSI (14)

73.07

Momentum

Beta

0.43

vs Market

52W High

$421.58

1.51% below

52W Low

$269.78

53.91% above

Volume

876.48K

Avg 954.50K

P/B

20.37

Price-to-book

ROE

162.88%

Return on equity

Free Float

99.75%

Public shares

Shariah Compliance8 STANDARDS

✗ Amgen Inc (AMGN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AMGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.04%

+16.88%

+23.49%

+12.47%

YTD

+26.86%

+43.03%

+56.09%

+80.78%

Financials & Valuation

TTM · Annual

Total Revenue	$36.75B
Net Income	$7.71B
Revenue Growth (YoY)	+9.53%
Gross Margin	70.78%
Operating Margin	31.51%
Net Profit Margin	20.98%
ROE	162.88%
ROA · ROIC	9.84% · 15.60%

P/E Ratio	25.79
Forward P/E (FY1)	17.38
PEG Ratio	0.26
P/S	4.83
P/B	20.37
P/FCF	21.90
EPS Growth	+5.41%
Outstanding Shares	540.63M

Technical Indicators

50-Day SMA	$370.22
200-Day SMA	$349.38
RSI (14)	73.07
Beta	0.43
52-Week High	$421.58
52-Week Low	$269.78

Volume Today	876.48K
Avg Daily Volume (30D)	954.50K
Relative Volume	0.92x
Volatility (10D)	28.16
Volatility (30D)	26.51
Free Float	99.75%

Analyst Consensus

HOLD

Current Price $415.21

Mean Target $385.24

52W Low$269.78 52W High$421.58

Current

Target

$269.78 $421.58

Current Analyst target

-7.22% downside risk · 34 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S5NNL6

ISINUS0311621009

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.